Publication | Closed Access

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients

Pretreatment Neutrophil-to-lymphocyte RatioPrognostic BiomarkersUrologyGenitourinary CancerClinical ResponsesMedicineBiomarker TargetImmune Checkpoint InhibitorOncologyRadiation OncologyNovel Biomarker